GATC Health Executives Invited to Endpoints AI Day in NYC
IRVINE, Calif., October 22, 2026 – GATC Health’s Co-founder, Chairman, and Chief Technology Officer, Jayson Uffens, and SVP of Business Development, Mark Flather, recently attended the invite-only Endpoints AI Day in New York City. This premier event gathered the industry’s most influential voices at the intersection of AI and biopharma, including leaders from Bristol Myers Squibb, Recursion, and Anthropic. During the live editorial sessions and private networking, our team engaged with the frontier labs, pharma, and venture capital leaders shaping the future of medicine. We look forward to leveraging the strategic relationships and insights forged at this gathering to further accelerate our pioneering work.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
GATC Health Presents Digital Twin Technologies at Sanofi Vaccine Summit
CIO Eric Mathur’s SVABS presentation and interview IRVINE, Calif., October 7, 2026 – GATC Health Chief Innovation Officer Eric Mathur…
Read more
GATC Health Featured on Citeline’s In Vivo Podcast: A “FICO Score” for Drug Development
June 17, 2026 — In the episode, titled “GATC Health’s Derisq AI, A FICO Score For Drug Development,” GATC Health Chief…
Read more
Drug Discovery News Covers GATC’s PNAS Breakthrough, Extending Media Momentum Around GATC-1021
May 5, 2026 — GATC Health is pleased to share additional media momentum stemming from the company’s recent PNAS publication on GATC-1021, i…
Read more